Company performance
Current Price
as of Jan 07, 2025$66.11
P/E Ratio
N/A
Market Cap
$11.83B
Description
Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline. The company was founded in 1988 and is headquartered in Bridgewater, NJ.
Metrics
Overview
- HQBridgewater, NJ
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- TickerINSM
- Price$66.11-0.77%
Trading Information
- Market cap$11.83B
- Float97.60%
- Average Daily Volume (1m)1,774,412
- Average Daily Volume (3m)1,531,377
- EPS-$5.56
Company
- Revenue$342.96M
- Rev growth (1yr)18.15%
- Net income-$220.52M
- Gross margin75.99%
- EBITDA margin-209.82%
- EBITDA-$196.02M
- EV$12.38B
- EV/Revenue36.09
- P/EN/A
- P/S33.49
- P/B24.46
Documents
SEC Filings
Earnings Calls